Bausch Health Companies Inc. (BHC)
Largest Insider Buys in Sector
BHC Stock Price History Chart
BHC Stock Performance
About Bausch Health Companies Inc.
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The …
Insider Activity of Bausch Health Companies Inc.
Over the last 12 months, insiders at Bausch Health Companies Inc. have bought $0 and sold $148,569 worth of Bausch Health Companies Inc. stock.
On average, over the past 5 years, insiders at Bausch Health Companies Inc. have bought $102.79M and sold $10.06M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 60,000 shares for transaction amount of $1.45M was made by Miller Steven D (director) on 2021‑11‑30.
List of Insider Buy and Sell Transactions, Bausch Health Companies Inc.
| 2024-12-02 | Sale | EVP, General Counsel | 440 0.0001% | $8.35 | $3,674 | +1.66% | ||
| 2024-09-06 | Sale | EVP, General Counsel | 13,370 0.0036% | $6.21 | $83,028 | +31.40% | ||
| 2024-03-04 | Sale | EVP, General Counsel | 6,313 0.0018% | $9.80 | $61,867 | -16.91% | ||
| 2023-12-05 | Sale | EVP, General Counsel | 220 <0.0001% | $7.38 | $1,624 | +13.07% | ||
| 2023-11-06 | Sale | EVP, General Counsel | 43 <0.0001% | $7.61 | $327 | +4.86% | ||
| 2023-09-06 | Sale | EVP, General Counsel | 6,685 0.0018% | $8.28 | $55,352 | -8.67% | ||
| 2023-03-06 | Sale | EVP, General Counsel | 495 0.0001% | $9.17 | $4,539 | -10.20% | ||
| 2023-03-03 | Sale | EVP, General Counsel | 780 0.0002% | $9.34 | $7,285 | -14.30% | ||
| 2023-02-28 | Sale | EVP, General Counsel | 292 <0.0001% | $9.32 | $2,721 | -15.31% | ||
| 2022-04-14 | Sale | U.S. President-Pharma Business | 1,595 0.0004% | $22.19 | $35,393 | -65.94% | ||
| 2022-03-15 | Sale | U.S. President-Pharma Business | 4,846 0.0014% | $22.20 | $107,581 | -65.00% | ||
| 2022-03-08 | Sale | Pres&Co-Head Bausch&Lomb/Int'l | 3,889 0.0011% | $21.76 | $84,625 | -64.35% | ||
| 2022-03-02 | Sale | Pres&Co-Head Bausch&Lomb/Int'l | 11,077 0.003% | $23.37 | $258,869 | -68.14% | ||
| 2022-03-02 | Sale | U.S. President-Pharma Business | 1,595 0.0004% | $23.37 | $37,275 | -68.14% | ||
| 2022-03-01 | Sale | Pres&Co-Head Bausch&Lomb/Int'l | 6,338 0.0018% | $23.82 | $150,971 | -67.14% | ||
| 2022-02-15 | Sale | U.S. President-Pharma Business | 3,251 0.0009% | $25.02 | $81,340 | -69.84% | ||
| 2022-01-18 | Sale | U.S. President-Pharma Business | 3,251 0.0009% | $26.63 | $86,574 | -70.45% | ||
| 2021-11-30 | director | 60,000 0.017% | $24.23 | $1.45M | -60.82% | |||
| 2021-08-05 | director | 2,800 0.0008% | $25.94 | $72,632 | -6.04% | |||
| 2021-08-04 | director | 20,000 0.0056% | $25.01 | $500,246 | -2.62% |
Insider Historical Profitability
| Paulson John | 25839035 7.0252% | $7.47 | 5 | 2 | +31.4% | |
| ValueAct Holdings, L.P. | director | 17931594 4.8753% | $7.47 | 19 | 3 | +19.98% |
| Pearson J. Michael | Chief Executive Officer | 1514664 0.4118% | $7.47 | 2 | 1 | +21.28% |
| Morfit G Mason | See Remarks | 1352941 0.3678% | $7.47 | 1 | 0 | +30.3% |
| UBBEN JEFFREY W | director | 1059793 0.2881% | $7.47 | 3 | 1 | +44.4% |
Institutional Investor Ownership
| ICAHN CARL C | $368.39M | 9.62 | 34.72M | 0% | +$0 | 3.29 | |
| GoldenTree Asset Management | $293.31M | 7.66 | 27.64M | 0% | +$0 | 25.67 | |
| Paulson & Co. | $280.52M | 7.32 | 26.44M | 0% | +$0 | 19.38 | |
| Franklin Templeton Investments | $168.18M | 4.39 | 15.85M | +0.32% | +$528,788.17 | 0.05 | |
| National Bank Of Canada Fi | $107.75M | 4.34 | 15.66M | +0.07% | +$80,874.83 | 0.18 |